AIOLOS BIO

aiolos-bio-logo

Long Description: Aiolos Bio is a biotech company focused on developing therapies for respiratory diseases like asthma as well as other immune conditions. The company is initially focused on advancing AIO-001, a monoclonal antibody therapy for moderate-to-severe asthma that only requires dosing every 6 months. Aiolos Bio was founded by an accomplished team with decades of drug development experience and leadership in the biotech industry.

#SimilarOrganizations #People #Financial #Website #More

AIOLOS BIO

Social Links:

Industry:
Biopharma Biotechnology Health Care

Founded:
2023-01-01

Address:
San Francisco, California, United States

Country:
United States

Website Url:
http://www.aiolosbio.com

Total Employee:
11+

Status:
Active

Total Funding:
245 M USD

Technology used in webpage:
British Server Location


Similar Organizations

day-one-biopharmaceuticals-logo

Day One Biopharmaceuticals

Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.

not_available_image

Georgiamune

Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.

gritstone-bio-logo

Gritstone Bio

Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.

harmony-biosciences-logo

Harmony Biosciences

Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.

nephrodi-therapeutics-logo

NephroDI Therapeutics

NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.

ocean-biomedical-logo

Ocean Biomedical

Ocean Biomedical is a biotechnology company that accelerates new discoveries in the world of medicine.

ocugen-logo

Ocugen

Ocugen is a clinical stage biopharmaceutical company.

vera-therapeutics-logo

Vera Therapeutics

Vera Therapeutics is a biotechnology company developing innovative biologic therapeutics with transformative clinical potential.


Current Advisors List

john-milligan_image

John Milligan Board Director @ Aiolos Bio
Board_member

Current Employees Featured

khurem-farooq_image

Khurem Farooq
Khurem Farooq CEO and Co-Founder @ Aiolos Bio
CEO and Co-Founder

Founder


khurem-farooq_image

Khurem Farooq

Investors List

forbion-capital-partners_image

Forbion Capital Partners

Forbion Capital Partners investment in Series A - Aiolos Bio

atlas-venture_image

Atlas Venture

Atlas Venture investment in Series A - Aiolos Bio

sofinnova-ventures_image

Sofinnova Investments

Sofinnova Investments investment in Series A - Aiolos Bio

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Series A - Aiolos Bio

bain-capital-life-sciences_image

Bain Capital Life Sciences

Bain Capital Life Sciences investment in Series A - Aiolos Bio

Official Site Inspections

http://www.aiolosbio.com

  • Host name: 213.11.111.34.bc.googleusercontent.com
  • IP address: 34.111.11.213
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Aiolos Bio"

Aiolos Bio - Crunchbase Company Profile & Funding

Aiolos Bio is a biotech company developing innovative therapies for respiratory diseases and immune conditions.See details»

Aiolos Bio - LinkedIn

Today we are proud to announce a definitive merger agreement under which GSK will acquire Aiolos Bio for a total value of $1.4B. This deal will enable us to advance our mission of helping patients ...See details»

GSK enters agreement to acquire Aiolos Bio

Stock-exchange announcement For media and investors only Stock-exchange announcement 2 About Aiolos Bio Founded in 2023, Aiolos Bio is a San Francisco, USA and London, UK-based โ€ฆSee details»

GSK completes acquisition of Aiolos Bio

Feb 15, 2024 GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the โ€ฆSee details»

Aiolos Bio Company Profile 2024: Valuation, Investors ... - PitchBook

Aiolos Bio General Information Description. Operator of a clinical-stage biopharmaceutical company intended to focus on addressing the unmet treatment needs of patients with โ€ฆSee details»

GSK completes acquisition of Aiolos Bio for up to $1.4 bln

Feb 15, 2024 GSK said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions.See details»

GSK completes acquisition of Aiolos Bio โ€“ Company โ€ฆ

Issued: 15 February 2024, London UK GSK completes acquisition of Aiolos Bio GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of Aiolos Bio โ€ฆSee details»

GSK Boosts Respiratory Portfolio with $1.4 Billion ... - Investopedia

Jan 9, 2024 GSK PLC on Tuesday announced a deal to acquire asthma drugmaker Aiolos Bio Inc. for $1.4 billion. The deal includes a $1 billion upfront payment and $400 million in success โ€ฆSee details»

GSK to Acquire Aiolos Bio, Expands Respiratory Portfolio

On Jan. 9, 2024, GSK and Aiolos Bio, a clinical-stage biopharmaceutical company specializing in the treatment of respiratory and inflammatory conditions, announced that they have entered โ€ฆSee details»

Aiolos Bio - Bain Capital Life Sciences

Founded in 2023, Aiolos Bio is a San Francisco, USA and London, UK-based clinical-stage, private, biopharmaceutical company dedicated to revolutionising the treatment landscape for โ€ฆSee details»

Aiolos Bio - Craft

Aiolos Bio $245 m in total funding,. See insights on Aiolos Bio including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»

Forbion co-leads $245 million Series A financing of Aiolos

Oct 24, 2023 Our team has a long history of successful drug development in respiratory and immunological diseases โ€“ collectively amassing more than 30 FDA approvals โ€“ and seeks to โ€ฆSee details»

Aiolos Bio - Forbion

Www.aiolosbio.com Worked on by. Wouter Joustra, MSc General Partner. Read more Audrey Cacaly, MSc Principal. Audrey joined the Forbion team in 2021 Read more Alice Vickers, PhD โ€ฆSee details»

Data retrieved successfully. - Bain Capital

Oct 24, 2023 Bain Capital, LP is one of the worldโ€™s leading multi-asset alternative investment firms. With offices on four continents, our global team aligns our interests with those of our โ€ฆSee details»

Aiolos Bio Launches with $245 Million Series A ... - Business Wire

Oct 24, 2023 For more information, please visit www.aiolosbio.com. Contacts. Media: For Aiolos Bio: Scott Lessne Stanton [email protected] (646) 502-3569 Contacts.See details»

Aiolos Bio launches with $245M to advance severe asthma med

Oct 24, 2023 A consistent theme of 2023 has been that advanced assets attract seismic capital and a newly launched biotech adds more proof to the pile. Aiolos Bio is jetting out of stealth โ€ฆSee details»

GSK Enters Agreement to Acquire Aiolos Bio | Nasdaq

Jan 9, 2024 SAN FRANCISCO& LONDON---- GSK plc and Aiolos Bio, Inc. today announced that they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage โ€ฆSee details»

GSK enters agreement to acquire Aiolos Bio

Jan 9, 2024 Acquisition expands GSKโ€™s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody.See details»

Aiolos Bio Launches with $245 Million Series A Investment to

Oct 24, 2023 SAN FRANCISCO & LONDON--(BUSINESS WIRE)-- Aiolos Bio, Inc. (โ€œAiolosโ€ or โ€œthe Companyโ€) today announced its launch as a clinical-stage biopharmaceutical company โ€ฆSee details»

Aiolos Bio raises $245M on prospect of better asthma drug

Oct 24, 2023 Aiolos Bio raises $245M on prospect of better asthma drug The Series A funding round ranks among the largest in the biotech industry this year, with investors including Atlas, โ€ฆSee details»

linkstock.net © 2022. All rights reserved